A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Lung transplant recipients have the highest risk of readmission after the index admission among solid organ transplant patients. We hypothesize that targeted, individualized rehabilitation plans will reduce the risk of unplanned readmission in the first year after lung transplantation.To address this hypothesis, we will conduct a prospective cohort study of …
The Laboratory for Cognition and Neural Stimulation (LCNS) is currently recruiting individuals who have suffered from stroke and are now experiencing aphasia, a loss or impairment of language abilities, for a clinical trial. The purpose of this study is to determine if Transcranial Magnetic Stimulation (TMS), a form of non-invasive …
This is a multicenter study to evaluate the long-term safety and tolerability of mavacamten in participants with nHCM who completed MAVERICK-HCM through Week 24 and enroll into this study within 3 months. All participants will receive active study drug as described below, but their status (active or placebo) in the …
OCPs increase the risk of MetS specifically by producing an atherogenic lipoprotein phenotype, increasing blood pressure and/ or body weight while metformin modestly decreases MetS risk by decreasing body weight and improving lipid phenotype. The combination of OCP and metformin (OCP, through lowering androgens, and metformin, through improvement in insulin …
The purpose of this study is to find out if a drug called dapagliflozin would be effective in improving the blood tests and symptoms related to your heart failure.
This is a pragmatic randomized multicenter, effectiveness study comparing active treatment of a sPDA to expectant management. This trial estimates the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.
This is a pilot study. Subjects with primary soft tissue sarcoma of the extremities may be eligible for this study. Subjects may participate in this study if they are at least 18 years of age. Most participants will be receiving care at the clinical practices of the University of Pennsylvania …
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …